Description
Name: Ganirelix
Synonym: Antagon; orgalutran; Ganirelixum
Cas No: 123246-29-7
Source: synthetic
Ganirelix has potential applications in all conditions where reduced sex-steroid secretion is advantageous, including assisted reproduction protocols, advanced prostatic carcinoma, benign prostatic hyperplasia, uterine fibroids, and endometriosis. It has the potential therapeutic advantage over GnRH agonists of avoiding the initial stimulation of sex-steroid secretion. This will avoid the disease flare produced by agonists in prostatic carcinoma (Cook and Sheridan, 2000) and reduce the time over which it must be administered in assisted reproduction protocols. It is producing a similar pregnancy rate to that obtained using leuprorelin but with fewer injections and a shorter protocol.
- Ganirelix
- Peptides API
Production Capacity:
500000
Delivery Timeframe:
Immediate
Incoterms:
CFR - Cost and Freight
CIF - Cost, Insurance and Freight
DDP - Delivered Duty Paid
DDU - Delivered Duty Unpaid
EXW - Ex Works
FOB - Free on Board
Packaging Details:
Not informed
More about
Hybio Pharmaceutical Co., Ltd
500-1000
Employees
1
Sales volume (USD)
40%
% Export sales
Year
Established
Business type
- Industry / Manufacturer
- Business Service
Keywords
- API Peptides
- FDF
- Liraglutide
- Semaglutide
- Terlipressin
- Atosiban Ver Mais
Contact and location
- Andrew Li
- +86 xxxxxxxx
- 深圳 / | China